Holen Sie sich die Stockscreener-App
4.795
7.05%
0.325
Handel nachbörslich:
4.78
-0.015
-0.31%
Schlusskurs vom Vortag:
$4.47
Offen:
$4.45
24-Stunden-Volumen:
847.58K
Relative Volume:
1.64
Marktkapitalisierung:
$63.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.71M
KGV:
-1.1252
EPS:
-4.2615
Netto-Cashflow:
$-19.77M
1W Leistung:
+9.00%
1M Leistung:
-12.52%
6M Leistung:
+30.38%
1J Leistung:
+30.74%
1-Tages-Spanne:
$4.42
$5.15
1-Wochen-Bereich:
$4.343
$5.15
52-Wochen-Spanne:
$3.20
$11.89
Cingulate Inc Stock (CING) Company Profile
Firmenname
Cingulate Inc
Sektor
Branche
Telefon
(913) 942-2300
Adresse
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.795 | 59.34M | 0 | -27.71M | -19.77M | -4.2615 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | ROTH MKM | Buy |
| 2023-12-22 | Herabstufung | Laidlaw | Buy → Hold |
Cingulate Inc Aktie (CING) Neueste Nachrichten
Cingulate stock reaffirmed at Buy by H.C. Wainwright ahead of FDA decision - Investing.com Canada
Cingulate Reshapes Board Structure and Leadership Roles - The Globe and Mail
Roth MKM Maintains Cingulate(CING.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Cingulate to reduce board size as directors opt not to seek re-election - Investing.com
Jeff Hargroves reappointed to Cingulate board as Class II; Jeff Ervin and Jay Roberts to not seek re-election - TradingView
Board reshuffle at Cingulate (NASDAQ: CING) as directors plan exit - Stock Titan
Cingulate Inc. (CING) schedules virtual annual meeting, equity plan vote - Stock Titan
CING: Building its cash position - MSN
Cingulate Inc.Warrants (NQ: CINGW - FinancialContent
Maxim Group Maintains Cingulate(CING.US) With Buy Rating, Maintains Target Price $8 - Moomoo
CING Should I Buy - Intellectia AI
Cingulate Inc. 2026 Q1 10-Q Filing: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Cingulate Reports Q1 2026 Financial Results, Grows Cash to $25.9M, Advances CTx-1301 ADHD NDA Toward FDA Decision - Minichart
Cingulate reports Q1 loss, raises cash runway into 2027 By Investing.com - Investing.com Nigeria
Cingulate reports Q1 loss, raises cash runway into 2027 - Investing.com India
Cingulate Inc. 1Q 2026: Revenue $0 Net loss $(9.31M) — 10-Q Summary - TradingView
Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cingulate (NASDAQ: CING) widens Q1 2026 loss while boosting cash for CTx-1301 launch prep - Stock Titan
Cingulate Reports Q1 2026: Cash Rises to $25.9M, Net Loss $9.3M - TradingView
Cash builds as Cingulate (NASDAQ: CING) readies CTx-1301 ahead of FDA date - Stock Titan
Press Release: Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for Lead ADHD Asset CTx-1301 - Moomoo
TradingKey - TradingKey
Cingulate (CING) EVP receives 3,422-share stock option award - Stock Titan
Why did Cingulate stock skyrocket today? - MSN
Cingulate (CING) to Release Quarterly Earnings on Thursday - MarketBeat
At least five PDUFA dates on FDA’s May docket - BioCentury
FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate - BioSpace
Cingulate Inc. (NASDAQ:CING) Short Interest Up 31.7% in April - MarketBeat
What's going on with Cingulate stock today? - MSN
Cingulate Inc. (NASDAQ: CING) registers 4.21M common shares for resale - Stock Titan
[EFFECT] Cingulate Inc. SEC Filing - Stock Titan
Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever - Insider Monkey
CING Options Volatility — NASDAQ:CING - TradingView
CING Options Chain — NASDAQ:CING - TradingView
Should I buy or sell Cingulate (CING) stock today | Q4 2025: Earnings Fall ShortShared Momentum Picks - Xã Châu Thành
CING (Cingulate Inc.) shares fall 2.8% after Q4 2025 EPS misses analyst estimates by a wide margin.Dividend Report - Xã Châu Thành
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
CING SEC FilingsCingulate Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cingulate (CING) Stock: Why Automation Investment (+8.72%) 2026-04-20Analyst Upgrade - Cổng thông tin điện tử tỉnh Lào Cai
Q1 EPS Estimates for Cingulate Increased by Analyst - MarketBeat
Cingulate Inc. (NASDAQ: CING) registers 4.21M resale shares; Falcon Creek holds 3.86M - Stock Titan
Research Analysts Issue Forecasts for Cingulate Q1 Earnings - MarketBeat
Finanzdaten der Cingulate Inc-Aktie (CING)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cingulate Inc-Aktie (CING) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Callahan Jennifer L. | SVP and CFO |
Feb 06 '26 |
Buy |
5.04 |
4,864 |
24,515 |
5,059 |
| Schaffer Shane J. | Chief Executive Officer |
Feb 06 '26 |
Buy |
5.04 |
6,809 |
34,317 |
10,175 |
| Brams Matthew | EVP and Chief Medical Officer |
Feb 06 '26 |
Buy |
5.04 |
1,946 |
9,808 |
4,656 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):